LIVN250117P30000
- 0.86
- 0.000.00%
LivaNova Newsroom
LivaNova Announces RECOVER Clinical Study Shows Meaningful Benefits Of It's VNS Therapy System In Select Secondary Endpoints For Unipolar Patients With Treatment-Resistant Depression; Results Published In Two Articles In 'Brain Stimulation'
Express News | LivaNova PLC - Active Treatment Arm Showed Significant Improvement Despite Primary Endpoint Not Met
Express News | Recover Clinical Study Shows Meaningful Benefits of Livanova’s Vns Therapy System in Select Secondary Endpoints for Unipolar Patients With Treatment-Resistant Depression
RECOVER Clinical Study Shows Meaningful Benefits of LivaNova's VNS Therapy System in Select Secondary Endpoints for Unipolar Patients With Treatment-Resistant Depression
"Laggard" Stocks With Expanding FCF Margins and Attractive FCF Yields – Goldman
LivaNova to Present Scientific Data at American Epilepsy Society 2024 Annual Meeting
Is Now The Time To Look At Buying LivaNova PLC (NASDAQ:LIVN)?
Wall Street Analysts Predict a 37.2% Upside in LivaNova (LIVN): Here's What You Should Know
LivaNova's OSPREY Sleep Apnea Trail on Aura6000 Meets Primary Endpoint
LivaNova Management to Meet With Needham
LivaNova to Present at the Stifel, Wolfe, and Piper Sandler Healthcare Conferences
Barclays Maintains LivaNova(LIVN.US) With Hold Rating, Maintains Target Price $61
Barclays Releases a Hold Rating on LivaNova (LIVN)
Mizuho Securities Maintains LivaNova(LIVN.US) With Buy Rating
LivaNova's OSPREY Trial Success Drives Buy Recommendation Amid Market Potential
Solid Earnings Reflect LivaNova's (NASDAQ:LIVN) Strength As A Business
Express News | LivaNova PLC - No Serious Adverse Device-Related or Procedure-Related Events Reported
LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints
Express News | LivaNova Announces Osprey Clinical Study Meets Primary Safety and Efficacy Endpoints
How Much Upside Is Left in LivaNova (LIVN)? Wall Street Analysts Think 38.2%